UBS Group AG - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 102 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2018. The put-call ratio across all filers is 2.89 and the average weighting 1.0%.

Quarter-by-quarter ownership
UBS Group AG ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$14,000
+1300.0%
68,194
+2104.1%
0.00%
Q3 2018$1,000
-97.0%
3,094
-95.3%
0.00%
Q2 2018$33,000
-59.3%
65,905
+89.2%
0.00%
Q1 2018$81,000
-19.0%
34,834
-1.5%
0.00%
Q4 2017$100,000
-54.3%
35,367
-53.7%
0.00%
Q3 2017$219,000
+35.2%
76,362
+16.2%
0.00%
Q2 2017$162,000
-38.6%
65,739
-10.0%
0.00%
Q1 2017$264,000
-61.0%
73,078
-61.7%
0.00%
Q4 2016$677,000
+11.5%
191,047
+27.2%
0.00%
Q3 2016$607,000
-40.9%
150,237
-35.8%
0.00%
-100.0%
Q2 2016$1,027,000
+299.6%
233,834
+243.8%
0.00%
Q1 2016$257,000
-93.6%
68,021
-73.5%
0.00%
-100.0%
Q4 2015$4,025,000
+422.7%
256,704
+251.6%
0.00%
+200.0%
Q3 2015$770,000
-64.2%
73,001
-14.4%
0.00%0.0%
Q2 2015$2,151,000
-8.7%
85,283
+0.8%
0.00%
-50.0%
Q1 2015$2,357,000
+93.5%
84,578
+26.8%
0.00%
+100.0%
Q4 2014$1,218,00066,7160.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q2 2018
NameSharesValueWeighting ↓
TSP Capital Management Group, LLC 813,273$3,286,0001.66%
RTW INVESTMENTS, LP 1,243,164$5,022,0001.52%
Marcus Capital, LLC 112,200$453,0000.44%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 996,178$4,024,0000.29%
Benchmark Capital Advisors 67,000$271,0000.20%
SUFFOLK CAPITAL MANAGEMENT LLC 360,299$1,456,0000.20%
COLUMBIA WANGER ASSET MANAGEMENT LLC 2,907,523$11,746,0000.15%
Virtus ETF Advisers LLC 59,537$241,0000.12%
Bellevue Group AG 160,000$646,0000.12%
PDT Partners, LLC 428,300$1,730,0000.10%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders